QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NYSEAMERICAN:SYNSynthetic Biologics Stock Price, Forecast & News

$0.59
+0.01 (+1.82 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.58
Now: $0.59
$0.61
50-Day Range N/A
52-Week Range
$0.25
Now: $0.59
$0.75
Volume383,053 shs
Average Volume435,527 shs
Market Capitalization$11.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Read More
Synthetic Biologics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees13
Market Cap$11.50 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$0.59
+0.01 (+1.82 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Synthetic Biologics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Synthetic Biologics
.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) released its earnings results on Tuesday, May, 5th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.07.
View Synthetic Biologics' earnings history
.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics shares reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

2 Wall Street analysts have issued 12-month price objectives for Synthetic Biologics' shares. Their forecasts range from $1.25 to $1.50. On average, they anticipate Synthetic Biologics' share price to reach $1.38 in the next year. This suggests a possible upside of 132.4% from the stock's current price.
View analysts' price targets for Synthetic Biologics
.

Has Synthetic Biologics been receiving favorable news coverage?

Media headlines about SYN stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Synthetic Biologics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Synthetic Biologics
.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 40,200 shares, a drop of 10.7% from the February 13th total of 45,000 shares. Based on an average daily volume of 282,600 shares, the days-to-cover ratio is presently 0.1 days.
View Synthetic Biologics' Short Interest
.

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.33%). Company insiders that own Synthetic Biologics stock include Randal J Kirk and Steven A Shallcross.
View institutional ownership trends for Synthetic Biologics
.

Which institutional investors are buying Synthetic Biologics stock?

SYN stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC.
View insider buying and selling activity for Synthetic Biologics
.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.59.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $11.50 million. Synthetic Biologics employs 13 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.